Related Experiment Videos
Inflammation and lipid-lowering treatment
1Department of Medicine, Baylor College of Medicine, 6565 Fannin, MS A-601, Houston, Texas 77030, USA.
Current Cardiology Reports
|September 12, 2000
Summary
Leukocyte adhesion molecules (CAMs) are key in atherosclerosis development and plaque instability. Soluble CAM levels, elevated in at-risk patients, decrease with lipid-lowering treatments, suggesting their use as novel inflammation markers.
Area of Science:
- Cardiovascular Science
- Immunology
- Biochemistry
Background:
- Leukocytes are central to atherogenesis, plaque instability, and thrombosis.
- Leukocyte-endothelial cell adhesion molecules (CAMs) regulate leukocyte-vessel wall interactions.
- Elevated soluble CAMs are observed in dyslipidemia and other atherosclerosis risk factors.
Purpose of the Study:
- To investigate the role of soluble CAMs as markers in atherosclerosis.
- To assess the impact of lipid-modifying therapy on soluble CAM levels.
- To explore novel inflammation markers for identifying high-risk individuals and evaluating treatment efficacy.
Main Methods:
- Analysis of leukocyte-endothelial cell adhesion molecules (CAMs).
- Measurement of soluble CAM levels in patients with dyslipidemia and other risk factors.
- Evaluation of changes in soluble CAM levels following lipid-modifying therapy.
Main Results:
- Soluble CAM levels are elevated in individuals with dyslipidemia and other cardiovascular risk factors.
- Lipid-modifying therapy effectively reduces soluble CAM levels.
- CAMs show potential as indicators of inflammatory processes in atherosclerosis.
Conclusions:
- Soluble CAMs are implicated in the pathogenesis of atherosclerosis.
- Reduced soluble CAM levels following treatment suggest therapeutic efficacy.
- Novel CAM markers may aid in identifying individuals at high risk for cardiovascular events and monitoring antiatherosclerotic therapies.